文献速递浆细胞疾病造血干细胞移植与细胞治疗

在实验性小鼠模型中比较针对恶性血液病的抗体免疫疗法

Comparison of antibody-based immunotherapeutics for malignant hematological disease in an experimental murine model.
PubMed 文献 · Blood Adv · 2024-01-01

研究建立靶向Slamf7的同基因小鼠模型,直接比较单克隆抗体、双特异性T细胞衔接器和CAR-T三种免疫疗法对表达Slamf7的MPC-11多发性骨髓瘤细胞的作用。三种疗法体内均显示抗肿瘤效果,但Slamf7-BiTE引起明显体重下降和全身不适,Slamf7-CART输注后副作用较轻;在异基因移植背景下,Slamf7-BiTE和Slamf7-CART活性维持,而Slamf7-mAb抗骨髓瘤活性增强。

要点

  • Slamf7-BiTE和Slamf7-CART在体外有效杀伤MPC-11细胞,不依赖Slamf7自身连接介导的抑制信号。
  • 体内三种免疫疗法均对表达Slamf7的靶细胞显示抗肿瘤效果。
  • Slamf7-BiTE引起明显体重下降和全身不适,Slamf7-CART输注后副作用较轻。

核心结论

  • 该模型忠实再现了人类免疫治疗后的疗效和副作用,有助于开发和改进免疫疗法,并可能帮助设计减轻稳态和异基因干细胞移植中不良效应的新方法。

研究设计与样本

  • 研究建立同基因小鼠模型,靶向进化保守的Slamf7免疫受体,该受体由小鼠多发性骨髓瘤细胞系MPC-11天然表达,用于直接比较三种靶向Slamf7的免疫疗法:单克隆抗体(mAb)、双特异性T细胞衔接器(BiTE)和嵌合抗原受体T细胞(CAR-T)。

主要发现

  • Slamf7-BiTE和Slamf7-CART在体外有效杀伤MPC-11细胞,不依赖Slamf7自身连接介导的抑制信号。
  • 将大鼠抗小鼠Slamf7抗体的恒定区嵌合为小鼠Fc-免疫球蛋白G2a以增强效应功能后,Slamf7-mAb通过结合Fcγ受体IV触发抗原特异性抗体依赖性细胞毒作用。
  • 体内三种免疫疗法均对表达Slamf7的靶细胞显示抗肿瘤效果。
  • 与Slamf7-mAb不同,Slamf7-BiTE在实验动物中引起明显副作用,包括体重下降和全身不适,Slamf7-CART输注后也观察到程度较轻的类似副作用。
  • 在异基因移植中,与无移植 setting 相比,Slamf7-BiTE和Slamf7-CART活性维持,而Slamf7-mAb显示增强的抗骨髓瘤活性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antibody-based immunotherapies have revolutionized leukemia and lymphoma treatment, with animal studies being crucial in evaluating effectiveness and side effects. By targeting the evolutionary conserved Slamf7 immune receptor, which is naturally expressed by the murine multiple myeloma cell line MPC-11, we have developed a syngeneic mouse model for direct comparison of 3 immunotherapies: monoclonal antibodies (mAb), bispecific T-cell engagers (BiTE), and chimeric antigen receptor (CAR) T cells (CART), all targeting Slamf7. Slamf7-BiTE is a bispecific single-chain antibody consisting of α-Slamf7 and α-CD3 Fv fragments joined through a Gly-Ser linker, and Slamf7-CART comprises the α-Slamf7 Fv fragment fused to the msCD8α transmembrane and msCD28, 4-1BB, and CD3ζ intracellular signaling domains. Slamf7-BiTE and Slamf7-CART effectively killed MPC-11 cells in vitro, independently of Slamf7-mediated inhibitory signaling by self-ligation. After chimerizing the constant region of the rat-anti-mouse Slamf7 antibody to mouse Fc-immunoglobulin G2a for enhanced effector functions, Slamf7-mAb triggered antigen-specific antibody-dependent cellular cytotoxicity by binding to Fcγ receptor IV. In vivo, all 3 immunotherapies showed antitumor effects against Slamf7-expressing targets. Unlike Slamf7-mAb, Slamf7-BiTE led to considerable side effects in test animals, including weight loss and general malaise, which were also observed to a lesser extent after Slamf7-CART infusion. In allogeneic transplant, Slamf7-BiTE and Slamf7-CART maintained activity compared with the nontransplant setting, whereas Slamf7-mAb displayed enhanced antimyeloma activity. In summary, our model faithfully replicates treatment efficacy and side effects detected after human immunotherapy. It aids in developing and improving immunotherapies and may help devise novel approaches to mitigate undesired effects in steady state and allogeneic stem cell transplantation.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Frebel K, Albring JC, Wohlgemuth A, et al. Comparison of antibody-based immunotherapeutics for malignant hematological disease in an experimental murine model. Blood Adv. 2024. PMID: 38197968. doi:10.1182/bloodadvances.2023011647

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。